Clinicopathological features and prognostic significance of HER2 expression in gastric cancer

Ji Soo Park, SunYoung Rha, Hyuncheol Chung, Minkyu Jung, Ki Hyang Kim, Hyun Jung Jun, Hyunki Kim, Ji Yeong An, Hyoung Il Kim, Jae Ho Cheong, WooJin Hyung, Sung Hoon Noh, Hyo Song Kim

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: HER2 positivity is reported to be <20% in gastric cancer. Clinicopathological characteristics will be helpful to understand the biological features of HER2-positive gastric cancer. Methods: A total of 813 gastric cancer patients who underwent HER2 testing between January 2005 and December 2010 were included in this study. Results: Ninety-five (11.7%) patients had HER2-positive gastric cancer. Elevated serum carcinoembryonic antigen (CEA) concentration [odds ratio (OR), 5.629; p < 0.001] and differentiated histology (OR, 3.717; p = 0.002) were significant predictive factors for HER2 positivity in localized disease. For recurrent or metastatic disease, elevated serum CEA concentration (OR, 2.545; p < 0.001), differentiated histology (OR, 3.299; p < 0.001), pulmonary metastasis (OR, 3.321; p = 0.001), and distant lymph node metastasis (OR, 2.286; p = 0.002) were significant predictive factors. Median disease-free survival (DFS) was shorter in HER2-positive patients than in others, especially in stage I or II disease (24.7 vs. 49.2 months; p < 0.001). Among HER2-negative patients with stage II diseases, patients who received adjuvant chemotherapy had longer DFS than others (42.2 vs. 30.7 months; p = 0.025). Conclusions: Clinicopathological factors may be useful in predicting the HER2 positivity of gastric cancer. Further studies are needed to understand the molecular basis of HER2-positive gastric cancer.

Original languageEnglish
Pages (from-to)147-156
Number of pages10
JournalOncology (Switzerland)
Volume88
Issue number3
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Stomach Neoplasms
Odds Ratio
Carcinoembryonic Antigen
Disease-Free Survival
Histology
Neoplasm Metastasis
Adjuvant Chemotherapy
Serum
Lymph Nodes
Lung

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Park, Ji Soo ; Rha, SunYoung ; Chung, Hyuncheol ; Jung, Minkyu ; Kim, Ki Hyang ; Jun, Hyun Jung ; Kim, Hyunki ; An, Ji Yeong ; Kim, Hyoung Il ; Cheong, Jae Ho ; Hyung, WooJin ; Noh, Sung Hoon ; Kim, Hyo Song. / Clinicopathological features and prognostic significance of HER2 expression in gastric cancer. In: Oncology (Switzerland). 2015 ; Vol. 88, No. 3. pp. 147-156.
@article{f7ef497242cd47909480791ebb22ca9a,
title = "Clinicopathological features and prognostic significance of HER2 expression in gastric cancer",
abstract = "Background: HER2 positivity is reported to be <20{\%} in gastric cancer. Clinicopathological characteristics will be helpful to understand the biological features of HER2-positive gastric cancer. Methods: A total of 813 gastric cancer patients who underwent HER2 testing between January 2005 and December 2010 were included in this study. Results: Ninety-five (11.7{\%}) patients had HER2-positive gastric cancer. Elevated serum carcinoembryonic antigen (CEA) concentration [odds ratio (OR), 5.629; p < 0.001] and differentiated histology (OR, 3.717; p = 0.002) were significant predictive factors for HER2 positivity in localized disease. For recurrent or metastatic disease, elevated serum CEA concentration (OR, 2.545; p < 0.001), differentiated histology (OR, 3.299; p < 0.001), pulmonary metastasis (OR, 3.321; p = 0.001), and distant lymph node metastasis (OR, 2.286; p = 0.002) were significant predictive factors. Median disease-free survival (DFS) was shorter in HER2-positive patients than in others, especially in stage I or II disease (24.7 vs. 49.2 months; p < 0.001). Among HER2-negative patients with stage II diseases, patients who received adjuvant chemotherapy had longer DFS than others (42.2 vs. 30.7 months; p = 0.025). Conclusions: Clinicopathological factors may be useful in predicting the HER2 positivity of gastric cancer. Further studies are needed to understand the molecular basis of HER2-positive gastric cancer.",
author = "Park, {Ji Soo} and SunYoung Rha and Hyuncheol Chung and Minkyu Jung and Kim, {Ki Hyang} and Jun, {Hyun Jung} and Hyunki Kim and An, {Ji Yeong} and Kim, {Hyoung Il} and Cheong, {Jae Ho} and WooJin Hyung and Noh, {Sung Hoon} and Kim, {Hyo Song}",
year = "2015",
month = "1",
day = "1",
doi = "10.1159/000368555",
language = "English",
volume = "88",
pages = "147--156",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "3",

}

Park, JS, Rha, S, Chung, H, Jung, M, Kim, KH, Jun, HJ, Kim, H, An, JY, Kim, HI, Cheong, JH, Hyung, W, Noh, SH & Kim, HS 2015, 'Clinicopathological features and prognostic significance of HER2 expression in gastric cancer', Oncology (Switzerland), vol. 88, no. 3, pp. 147-156. https://doi.org/10.1159/000368555

Clinicopathological features and prognostic significance of HER2 expression in gastric cancer. / Park, Ji Soo; Rha, SunYoung; Chung, Hyuncheol; Jung, Minkyu; Kim, Ki Hyang; Jun, Hyun Jung; Kim, Hyunki; An, Ji Yeong; Kim, Hyoung Il; Cheong, Jae Ho; Hyung, WooJin; Noh, Sung Hoon; Kim, Hyo Song.

In: Oncology (Switzerland), Vol. 88, No. 3, 01.01.2015, p. 147-156.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinicopathological features and prognostic significance of HER2 expression in gastric cancer

AU - Park, Ji Soo

AU - Rha, SunYoung

AU - Chung, Hyuncheol

AU - Jung, Minkyu

AU - Kim, Ki Hyang

AU - Jun, Hyun Jung

AU - Kim, Hyunki

AU - An, Ji Yeong

AU - Kim, Hyoung Il

AU - Cheong, Jae Ho

AU - Hyung, WooJin

AU - Noh, Sung Hoon

AU - Kim, Hyo Song

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: HER2 positivity is reported to be <20% in gastric cancer. Clinicopathological characteristics will be helpful to understand the biological features of HER2-positive gastric cancer. Methods: A total of 813 gastric cancer patients who underwent HER2 testing between January 2005 and December 2010 were included in this study. Results: Ninety-five (11.7%) patients had HER2-positive gastric cancer. Elevated serum carcinoembryonic antigen (CEA) concentration [odds ratio (OR), 5.629; p < 0.001] and differentiated histology (OR, 3.717; p = 0.002) were significant predictive factors for HER2 positivity in localized disease. For recurrent or metastatic disease, elevated serum CEA concentration (OR, 2.545; p < 0.001), differentiated histology (OR, 3.299; p < 0.001), pulmonary metastasis (OR, 3.321; p = 0.001), and distant lymph node metastasis (OR, 2.286; p = 0.002) were significant predictive factors. Median disease-free survival (DFS) was shorter in HER2-positive patients than in others, especially in stage I or II disease (24.7 vs. 49.2 months; p < 0.001). Among HER2-negative patients with stage II diseases, patients who received adjuvant chemotherapy had longer DFS than others (42.2 vs. 30.7 months; p = 0.025). Conclusions: Clinicopathological factors may be useful in predicting the HER2 positivity of gastric cancer. Further studies are needed to understand the molecular basis of HER2-positive gastric cancer.

AB - Background: HER2 positivity is reported to be <20% in gastric cancer. Clinicopathological characteristics will be helpful to understand the biological features of HER2-positive gastric cancer. Methods: A total of 813 gastric cancer patients who underwent HER2 testing between January 2005 and December 2010 were included in this study. Results: Ninety-five (11.7%) patients had HER2-positive gastric cancer. Elevated serum carcinoembryonic antigen (CEA) concentration [odds ratio (OR), 5.629; p < 0.001] and differentiated histology (OR, 3.717; p = 0.002) were significant predictive factors for HER2 positivity in localized disease. For recurrent or metastatic disease, elevated serum CEA concentration (OR, 2.545; p < 0.001), differentiated histology (OR, 3.299; p < 0.001), pulmonary metastasis (OR, 3.321; p = 0.001), and distant lymph node metastasis (OR, 2.286; p = 0.002) were significant predictive factors. Median disease-free survival (DFS) was shorter in HER2-positive patients than in others, especially in stage I or II disease (24.7 vs. 49.2 months; p < 0.001). Among HER2-negative patients with stage II diseases, patients who received adjuvant chemotherapy had longer DFS than others (42.2 vs. 30.7 months; p = 0.025). Conclusions: Clinicopathological factors may be useful in predicting the HER2 positivity of gastric cancer. Further studies are needed to understand the molecular basis of HER2-positive gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=84924245350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924245350&partnerID=8YFLogxK

U2 - 10.1159/000368555

DO - 10.1159/000368555

M3 - Article

C2 - 25402270

AN - SCOPUS:84924245350

VL - 88

SP - 147

EP - 156

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3

ER -